WHO Sounds Warning Over Acute Lack of Weight-Loss Injections

Fewer than one in 10 patients that would benefit from obesity jabs including Wegovy have access to them, caution the WHO as it releases its first recommendations on the therapies.

Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for more widespread and fairer access to GLP-1 medication.

Per estimates, more than two billion will be obese by 2030 unless action is taken.

"Our new guidance recognises that excess weight is a lifelong illness that can be treated with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are significant barriers to widespread access to the injections that can assist patients in reducing significant weight, explains the organization.

GLP-1 Therapy Scarcity

Even under the current most optimistic outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of those who need them, as stated by the WHO.

The guideline calls on governments and firms to expand access, through approaches like patent sharing.

Exclusive production rights on a key compound – the primary ingredient of a leading brand – is set to lapse in several nations in 2026.

The Way Weight-Loss Injections Function

GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and increase feelings of fullness so users reduce food intake.

Patients commonly start to lose weight in the initial weeks of beginning the regular doses.

Studies indicates people may put most of the weight back on a year later of halting the drug, because their normal appetite return.

Being carrying excess weight elevates your chance for developing diseases, such as diabetes, heart disease, brain attack, and specific cancers.

Obesity concerns people in every country and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.